Virtual screening and molecular dynamics simulations reveal insights into drug repurposing strategies against New Delhi metallo-β-lactamase

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Letters in Drug Design & Discovery

• Publication date

  2025-11-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.lddd.2025.100156
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• ESKAPE pathogens rapidly develop resistance against antibiotics in development in vitro

  2025cited by this paper
• ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics

  2024cited by this paper
• Atogepant: Mechanism of action, clinical and translational science

  2024cited by this paper
• Antimicrobial Resistance: A Growing Serious Threat for Global Public Health

  2023cited by this paper
• Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review

  2023cited by this paper
• Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.

  2023cited by this paper
• Discovery of isatin-β-methyldithiocarbazate derivatives as New Delhi metallo- β-lactamase-1 (NDM-1) inhibitors against NDM-1 producing clinical isolates.

  2023cited by this paper
• HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

  2023cited by this paper
• Revisiting ESKAPE Pathogens: virulence, resistance, and combating strategies focusing on quorum sensing

  2023cited by this paper
• The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

  2022cited by this paper
• Stereochemically altered cephalosporins as potent inhibitors of New Delhi metallo-β-lactamases.

  2022cited by this paper
• Dihydroxyphenyl-substituted thiosemicarbazone: A potent scaffold for the development of metallo-β-lactamases inhibitors and antimicrobial.

  2022cited by this paper
• Sildenafil in Ophthalmology: An update.

  2021cited by this paper
• 2-Mercaptomethyl Thiazolidines (MMTZs) Inhibit All Metallo-β-Lactamase Classes by Maintaining a Conserved Binding Mode.

  2021cited by this paper
• Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales

  2021cited by this paper
• Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine.

  2020cited by this paper
• Discovery of the Novel Inhibitor Against New Delhi Metallo-β-Lactamase Based on Virtual Screening and Molecular Modelling

  2020cited by this paper
• Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline

  2020cited by this paper
• A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2

  2020cited by this paper
• Antibiotic resistance and persistence—Implications for human health and treatment perspectives

  2020cited by this paper
• Structure-guided optimization of D-captopril for discovery of potent NDM-1 inhibitors.

  2020cited by this paper
• Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

  2020cited by this paper
• Metformin as Anti-Aging Therapy: Is It for Everyone?

  2019cited by this paper
• The Concept of an Ideal Antibiotic: Implications for Drug Design

  2019cited by this paper
• Discovery of NDM-1 inhibitors from natural products.

  2019cited by this paper
• Molecular and computational approaches to understand resistance of New Delhi metallo β-lactamase variants (NDM-1, NDM-4, NDM-5, NDM-6, NDM-7)-producing strains against carbapenems

  2018cited by this paper
• Rhodanine as a Potent Scaffold for the Development of Broad-Spectrum Metallo-β-lactamase Inhibitors.

  2018cited by this paper
• Aromatic interactions at the ligand-protein interface: Implications for the development of docking scoring functions.

  2018cited by this paper
• First identification of isatin-β-thiosemicarbazones as novel inhibitors of New Delhi metallo-β-lactamase-1: Chemical synthesis, biological evaluation and molecular simulation

  2017cited by this paper
• Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-β-lactamases

  2017cited by this paper
• Inhibition of New Delhi Metallo-β-Lactamase 1 (NDM-1) Producing Escherichia coli IR-6 by Selected Plant Extracts and Their Synergistic Actions with Antibiotics

  2017cited by this paper
• Captopril analogues as metallo-β-lactamase inhibitors.

  2016cited by this paper
• B1-Metallo-β-Lactamases: Where Do We Stand?

  2016cited by this paper
• Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates

  2016cited by this paper
• Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens

  2016cited by this paper
• New Delhi metallo-β-lactamase-1: structure, inhibitors and detection of producers.

  2016cited by this paper
• The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities

  2015cited by this paper
• pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures

  2015cited by this paper
• Differentiation of IncL and IncM Plasmids Associated with the Spread of Clinically Relevant Antimicrobial Resistance

  2015cited by this paper
• Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.

  2015cited by this paper
• A variety of roles for versatile zinc in metallo-β-lactamases.

  2014cited by this paper
• Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.

  2014cited by this paper
• Antibiotic resistance management

  2014cited by this paper
• Boronic acid-based enzyme inhibitors: a review of recent progress.

  2014cited by this paper
• AMA overcomes antibiotic resistance by NDM and VIM metallo-β-lactamases

  2014cited by this paper
• Metallo‐β‐lactamase structure and function

  2013cited by this paper
• Treatment Options for New Delhi Metallo-Beta-Lactamase-Harboring Enterobacteriaceae

  2013cited by this paper
• Drug repurposing and the medicinal chemist.

  2012cited by this paper
• Improving the Prediction of Absolute Solvation Free Energies Using the Next Generation OPLS Force Field.

  2012cited by this paper
• Identification and screening of carbapenemase-producing Enterobacteriaceae.

  2012cited by this paper
• NDM-4 Metallo-β-Lactamase with Increased Carbapenemase Activity from Escherichia coli

  2012cited by this paper
• New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition.

  2012cited by this paper
• Thalidomide: the tragedy of birth defects and the effective treatment of disease.

  2011cited by this paper
• Open Babel: An open chemical toolbox

  2011cited by this paper
• The emerging NDM carbapenemases.

  2011cited by this paper
• Three Decades of β-Lactamase Inhibitors

  2010cited by this paper
• New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?

  2010cited by this paper
• AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

  2009cited by this paper
• Characterization of a New Metallo-β-Lactamase Gene, blaNDM-1, and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India

  2009cited by this paper
• AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

  2009cited by this paper
• Metallo-β-lactamases: Novel Weaponry for Antibiotic Resistance in Bacteria

  2006cited by this paper
• Impact of antibiotic restrictions: the pharmaceutical perspective.

  2006cited by this paper
• Metallo-β-Lactamases: the Quiet before the Storm?

  2005cited by this paper
• MMFF VI. MMFF94s option for energy minimization studies

  1999cited by this paper
• Force field parametrization by weak coupling. Re-engineering SPC water

  1995cited by this paper
• A standard numbering scheme for the class A beta-lactamases.

  1991cited by this paper
• Characterization of beta-lactamases

  1989cited by this paper
• The structure of beta-lactamases.

  1980cited by this paper

• No citing papers are available for this paper.